share_log

Recursion Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

Recursion Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

Recursion Pharmaceuticals | 10-Q:2024財年三季報
美股SEC公告 ·  05:23

牛牛AI助理已提取核心訊息

Recursion Pharmaceuticals, a clinical-stage TechBio company, reported a net loss of $95.8 million for the third quarter of 2024, a slight increase from the $93.0 million loss in the same period of 2023. The nine-month period ended September 30, 2024, saw a net loss of $284.8 million, compared to $235.1 million in 2023. Despite the losses, operating revenue showed significant growth, with a more than 100% increase to $26.1 million for the quarter and a 62% rise to $54.3 million for the nine-month period. This growth was attributed to the strategic partnership with Roche, including a $30.0 million acceptance fee for a neuroscience Phenomap. Recursion's operating costs and expenses also rose, with research and development expenses climbing to $74.6 million for the quarter, up 7% from the previous year. General and administrative...Show More
Recursion Pharmaceuticals, a clinical-stage TechBio company, reported a net loss of $95.8 million for the third quarter of 2024, a slight increase from the $93.0 million loss in the same period of 2023. The nine-month period ended September 30, 2024, saw a net loss of $284.8 million, compared to $235.1 million in 2023. Despite the losses, operating revenue showed significant growth, with a more than 100% increase to $26.1 million for the quarter and a 62% rise to $54.3 million for the nine-month period. This growth was attributed to the strategic partnership with Roche, including a $30.0 million acceptance fee for a neuroscience Phenomap. Recursion's operating costs and expenses also rose, with research and development expenses climbing to $74.6 million for the quarter, up 7% from the previous year. General and administrative expenses increased by 29% to $37.8 million. The company's cash and cash equivalents stood at $427.6 million as of September 30, 2024, which they believe will fund operations for at least the next twelve months. Recursion continues to focus on its pipeline, including clinical trials for various treatments such as Cerebral Cavernous Malformation and Neurofibromatosis Type 2, and expects to share more data in the coming years. The company also highlighted its expanded collaboration with Google Cloud to support its drug discovery platform and the potential acquisition of Exscientia, which is subject to certain closing conditions.
臨床階段的TechBio公司Recursion Pharmaceuticals報告了2024年第三季度虧損9580萬美元,與2023年同期虧損9300萬美元相比略有增加。截至2024年9月30日的九個月期間,淨虧損爲28480萬美元,而2023年爲23510萬美元。儘管虧損,營業收入卻顯著增長,季度增長超過100%,達到2610萬美元,九個月期間增長62%,達到5430萬美元。這種增長歸因於與羅氏的戰略合作伙伴關係,其中包括針對神經系統Phenomap的3000萬美元接受費用。Recursion的營業成本和費用也上升,研發費用季度上升至7460萬美元,比去年同期增長了7%。總務及行政費用增長了...展開全部
臨床階段的TechBio公司Recursion Pharmaceuticals報告了2024年第三季度虧損9580萬美元,與2023年同期虧損9300萬美元相比略有增加。截至2024年9月30日的九個月期間,淨虧損爲28480萬美元,而2023年爲23510萬美元。儘管虧損,營業收入卻顯著增長,季度增長超過100%,達到2610萬美元,九個月期間增長62%,達到5430萬美元。這種增長歸因於與羅氏的戰略合作伙伴關係,其中包括針對神經系統Phenomap的3000萬美元接受費用。Recursion的營業成本和費用也上升,研發費用季度上升至7460萬美元,比去年同期增長了7%。總務及行政費用增長了29%,達到3780萬美元。截至2024年9月30日,該公司的現金及現金等價物爲42760萬美元,他們認爲可以支持至少未來12個月的運營。Recursion繼續專注於其產品線,包括針對多種治療方案的臨床試驗,如大腦海綿狀血管瘤和神經纖維瘤2型,並計劃在未來幾年分享更多數據。該公司還強調了與谷歌雲的擴大合作,以支持其藥物發現平台,以及潛在收購Exscientia,此收購取決於特定的關閉條件。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。